Everolimus prolongs progression-free survival for patients with neuroendocrine ... EurekAlert (press release) HOUSTON -- Combination treatment with everolimus, an inhibitor of the mammalian target rapamycin (mTOR), and octreotide has shown to improve progression-free survival for patients with advanced neuroendocrine tumors and a history of carcinoid syndrome, ... |
